Litu Zhang

List of Publications by Citations

Source: https://exaly.com/author-pdf/3978305/litu-zhang-publications-by-citations.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20 480 12 20 g-index

20 609 6 avg, IF L-index

#	Paper	IF	Citations
20	High frequency of submicroscopic genomic aberrations detected by tiling path array comparative genome hybridisation in patients with isolated congenital heart disease. <i>Journal of Medical Genetics</i> , 2008 , 45, 704-9	5.8	102
19	Haploinsufficiency of TAB2 causes congenital heart defects in humans. <i>American Journal of Human Genetics</i> , 2010 , 86, 839-49	11	75
18	Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients. <i>Journal of Cancer</i> , 2018 , 9, 494-501	4.5	54
17	Epigallocatechin-3-gallate inhibits cell growth, induces apoptosis and causes Sphase arrest in hepatocellular carcinoma by suppressing the AKT pathway. <i>International Journal of Oncology</i> , 2014 , 44, 791-6	4.4	46
16	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. <i>Pharmacology & Therapeutics</i> , 2020 , 216, 107672	13.9	31
15	Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 193	21	27
14	miR-155, miR-96 and miR-99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma. <i>Oncology Letters</i> , 2019 , 18, 3381-3387	2.6	26
13	(-)-Epigallocatechingallate induces apoptosis in B lymphoma cells via caspase-dependent pathway and Bcl-2 family protein modulation. <i>International Journal of Oncology</i> , 2015 , 46, 1507-15	4.4	23
12	Peripheral blood lymphocyte subset levels differ in patients with hepatocellular carcinoma. <i>Oncotarget</i> , 2016 , 7, 77558-77564	3.3	17
11	Screening of 99 Danish patients with congenital heart disease for GATA4 mutations. <i>Genetic Testing and Molecular Biomarkers</i> , 2006 , 10, 277-80		16
10	Characterization of a t(5;8)(q31;q21) translocation in a patient with mental retardation and congenital heart disease: implications for involvement of RUNX1T1 in human brain and heart development. <i>European Journal of Human Genetics</i> , 2009 , 17, 1010-8	5.3	15
9	Integrated analysis of differentially expressed mRNAs and miRNAs between hepatocellular carcinoma and their matched adjacent normal liver tissues. <i>Oncology Reports</i> , 2015 , 34, 325-33	3.5	12
8	An Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China. <i>PLoS ONE</i> , 2016 , 11, e0168795	3.7	11
7	Diagnostic value of plasma HSP90Ilevels for detection of hepatocellular carcinoma. <i>BMC Cancer</i> , 2020 , 20, 6	4.8	9
6	Flowers of Camellia nitidissima cause growth inhibition, cell-cycle dysregulation and apoptosis in a human esophageal squamous cell carcinoma cell line. <i>Molecular Medicine Reports</i> , 2016 , 14, 1117-22	2.9	7
5	Plasma HSP90AA1 Predicts the Risk of Breast Cancer Onset and Distant Metastasis. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 639596	5.7	6
4	Prognostic Value of C-Reactive Protein, Glasgow Prognostic Score, and C-Reactive Protein-to-Albumin Ratio in Colorectal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 637	76 5 0	2

LIST OF PUBLICATIONS

3	The High Ratio of the Plasma miR-96/miR-99b Correlated With Poor Prognosis in Patients With Metastatic Colorectal Cancer <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 799060	5.6	1
2	Plasma Levels of Heat Shock Protein 90 Alpha Associated With Colorectal Cancer Development. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 684836	5.6	Ο
1	Prognostic Evaluation of Metastasis-Related Lymphocyte/Monocyte Ratio in Stage I-III Breast Cancer Receiving Chemotherapy <i>Frontiers in Oncology</i> , 2021 , 11, 782383	5.3	О